Glimpses into treating GLILD - 03/08/23
Doi : 10.1016/j.jaci.2023.06.010
Timi Martelius, MD, PhD a, b, ⁎ 
, Mikko R.J. Seppänen, MD, PhD a, b, c, d
, Mikko R.J. Seppänen, MD, PhD a, b, c, d a Adult Immunodeficiency Unit, Infectious Diseases, Inflammation Center, University of Helsinki and HUS Helsinki University Hospital
b ERN-RITA Core Center, RITAFIN, Helsinki
c Rare Disease Center and Pediatric Research Center, Children and Adolescents, University of Helsinki and HUS Helsinki University Hospital
d Translational Immunology Research Program, University of Helsinki
∗Corresponding author: Timi Martelius, MD, PhD, Outpatient Clinic, Infectious Diseases, Inflammation Center, Helsinki University Hospital, HUS Group, PO Box 372 (Haartmaninkatu 4), 00029 HUS, Helsinki, Finland.Outpatient ClinicInfectious DiseasesInflammation CenterHelsinki University HospitalHUS GroupPO Box 372 (Haartmaninkatu 4)00029 HUSHelsinkiFinland
Key words : Interstitial lung disease, granulomatous-lymphocytic interstial lung disease, inborn errors of immunity, primary immunodeficiencies, immunodeficiency, common variable, glucocorticoids, immunomodulatory therapy
Il testo completo di questo articolo è disponibile in PDF.
Mappa
© 2023
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 152 - N° 2
P. 365-367 - agosto 2023 Ritorno al numero
Articolo precedente
- Moving forward with allergen immunotherapy: The significance of real-world studies
- Roy Gerth van Wijk, Paul van Daele
- The pulmonary effects of STAT3 deficiency
- Elizabeth A. Gilje, Jordan K. Abbott
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?